Duo biologic therapy using mepolizumab and omalizumab in refractory ABPA: two cases
Abstract Background Allergic bronchopulmonary aspergillosis (ABPA) presents with a wide range of symptom severity, with severe disease manifestations being harder to control through conventional inhalers. While corticosteroids remain a standard treatment option, their use is often hindered by signif...
Guardat en:
| Autors principals: | , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BMC
2025-09-01
|
| Col·lecció: | Allergy, Asthma & Clinical Immunology |
| Matèries: | |
| Accés en línia: | https://doi.org/10.1186/s13223-025-00985-0 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|